Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.

ABSTRACT:

Background

Although metastasis is ultimately responsible for about 90% of breast cancer mortality, the vast majority of breast-cancer-related deaths are due to progressive recurrences from non-metastatic disease. Current adjuvant therapies are unable to prevent progressive recurrences for a significant fraction of patients with breast cancer. Autologous tumor cell vaccines (ATCVs) are a safe and potentially useful strategy to prevent breast cancer recurrence, in a personalized and patient-specific manner, following standard-of-care tumor resection. Given the high intra-patient and inter-patient heterogeneity in breast cancer, it is important to understand which factors influence the immunogenicity of breast tumor cells in order to maximize ATCV effectiveness.

Methods

The rel

SUBMITTER: Ravindranathan S 

PROVIDER: S-EPMC6198508 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature